Shillong Herald

Geographic Atrophy Treatment Market is expected to grow steeply with a CAGR of ~30%, companies like Roche, NGM Biopharmaceuticals, Apellis Pharmaceuticals etc among others fueling the market

 Breaking News
  • No posts were found

Geographic Atrophy Treatment Market is expected to grow steeply with a CAGR of ~30%, companies like Roche, NGM Biopharmaceuticals, Apellis Pharmaceuticals etc among others fueling the market

February 24
14:49 2021
Geographic Atrophy Treatment Market is expected to grow steeply with a CAGR of ~30%, companies like Roche, NGM Biopharmaceuticals, Apellis Pharmaceuticals etc among others fueling the market

Geographic Atrophy Treatment Market

(Albany, US) DelveInsight’s Geographic Atrophy Market Analysis Report proffers a comprehensive outlay of the Geographic Atrophy Epidemiological analysis focusing on the incidence and diagnosed patient pool segmented on the basis of several factors, as well as the Geographic Atrophy market analysis in the 7MM (the US, EU5 (the UK, France, Germany, Italy and Spain) and Japan).

The report covers the Geographic Atrophy market trends covering key pharmaceutical companies in the market, upcoming as well as Geographic Atrophy marketed therapies, unmet needs, prevailing constraints and the factors driving the market size growth.

 

Some of the significant Geographic Atrophy Report Highlights:

  • Increase in GA market size anticipated for the study period 2018–2030 at a CAGR of 30.9%.
  • Globally, more than 5 million people are affected by GA.
  • In the year 2020, the total prevalent case of Geographic Atrophy was 2,969,911 cases in the 7MM. These cases are expected to grow with a significant CAGR in the study period 2018–2030.
  • In the 7MM, the total treated cases of Geographic Atrophy were 1,267,314 cases in 2020.
  • There are currently no approved Geographic Atrophy treatments. Several major players such as Apellis Pharmaceuticals, NGM Biopharmaceuticals, Roche, and many others are developing therapies for the Geographic Atrophy treatment. 
  • NGM Biopharmaceuticals is currently conducting the Phase 2 CATALINA study, a multicenter, randomized, double-masked, sham-controlled clinical trial, to assess the safety and efficacy of intravitreal injections (IVT) of NGM621 in patients with Geographic Atrophy secondary to age-related macular degeneration (AMD). 
  • NGM completed a multi-centre evaluation of NGM621 in an open-label, single-dose, and multiple-dose escalation study in participants with Geographic Atrophy Secondary to Age-related Macular Degeneration (NCT04014777).

 

Get more comprehensive insights into how Geographic Atrophy epidemiological trends are impacting current and forecasted Geographic Atrophy market @ Geographic Atrophy Epidemiology Analysis and Forecast

 

Some of Geographic Atrophy Companies:

  • Iveric Bio (formerly Ophthotech Corporation)
  • Apellis Pharmaceuticals
  • Hemera Biosciences
  • Allegro Ophthalmics
  • Stealth BioTherapeutics
  • Alkeus Pharmaceuticals
  • Gyroscope Therapeutics
  • Regenerative Patch Technologies
  • Roche/Genentech
  • Ionis Pharmaceuticals/Roche
  • CellCure Neurosciences (a subsidiary of Lineage Cell Therapeutics)
  • Janssen Research & Development
  • And Many Others 

Do you want to know how much market share the emerging therapies are going to capture by 2030? ContactGeographic Atrophy Marketed Therapies and Treatment Approaches and get a comprehensive understanding of the Geographic Atrophy therapeutic outlook.

The launch of the emerging therapies is expected to significantly impact the Geographic Atrophy treatment scenario in the upcoming years:-

 

Some of Geographic Atrophy Drugs Covered:

  • Zimura (avacincaptad pegol)
  • Pegcetacoplan
  • HMR59/AAVCAGsCD59
  • Risuteganib/ALG-1001/Luminate
  • Elamipretide
  • ALK-001
  • GT005
  • CPCB-RPE1
  • RO7171009/RG6147
  • IONIS-FB-LRx
  • OpRegen
  • Palucorcel/CNTO 2476
  • And Many Others

 

Know more about the collaborations, tie-ups, and therapies launch @ Geographic Atrophy Pipeline Therapies and Forecast 

 

Table of Contents:

1. Key Insights

2. Executive Summary of Geographic Atrophy

3. Competitive Intelligence Analysis for Geographic Atrophy

4. Geographic Atrophy: Market Overview at a Glance

5. Geographic Atrophy: Disease Background and Overview

6. Patient Journey

7. Geographic Atrophy Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Geographic Atrophy Treatment

11. Marketed Products

12. Emerging Therapies

13. Geographic Atrophy: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Geographic Atrophy

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/geographic-atrophy-ga-market

 

DelveInsght’s Competitive Intelligence Service includes a multidimensional coverage, helping to keep track of competitors and gain traction in the dynamic market by overcoming the challenges and expediting business growth through a strategic and tactical approach.   

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/geographic-atrophy-ga-market

Related Articles